Literature DB >> 3259971

Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals.

M Mihara1, Y Ohsugi, K Saito, T Miyai, M Togashi, S Ono, S Murakami, K Dobashi, F Hirayama, T Hamaoka.   

Abstract

Both NZB nu/+ and NZW nu/+ mice were microbially clean by cesarean section. The (NZB x NZW)F1 hybrid (NZB/W) nu/nu mice and nu/+ littermates were then generated by mating of NZB nu/+ with NZW nu/+mice under specific pathogen-free conditions. The female NZB/W F1 nu/nu mice did not develop autoimmune kidney disease, whereas all of nu/+ female littermates mice exhibited proteinuria and died of renal failure with a 50% survival time of 35 wk. Namely, nude mice had no signs of proteinuria up to the time of their death caused by other diseases rather than glomerulonephritis, and their mean survival time was greater than 45 wk. Nude mice had also no anti-ssDNA antibody in their serum. However, splenic B cells of NZB/W nude mice exhibited hyper-responsiveness to both LPS and B151-TRF2, a T cell-derived polyclonal B cell-stimulation factor, and produced large numbers of Ig-secreting cells and anti-TNP plaque-forming cells as well as anti-ssDNA antibody comparable to the nu/+ littermate mice. Interestingly, thymus-engrafted NZB/W nude mice developed autoimmune disease exemplified by the induction of anti-ssDNA antibody and proteinuria at approximately the same time as their nu/+ littermates. These results indicate that the B cell hyper-responsiveness found in NZB/W mice is apparently determined by the T cell-independent process, and T cells are obligatorily required for the development of autoimmune disease in NZB/W mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259971

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6.

Authors:  M Mihara; H Fukui; Y Koishihara; M Saito; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice.

Authors:  Hiroto Yoshida; Misato Hashizume; Miho Suzuki; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

Review 3.  Future prospects in biologic therapy for systemic lupus erythematosus.

Authors:  William Stohl
Journal:  Nat Rev Rheumatol       Date:  2013-09-10       Impact factor: 20.543

4.  Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Authors:  Ashley J Wilhelm; Amy S Major
Journal:  Int J Clin Rheumtol       Date:  2012-10-01

5.  T lymphocyte activation in systemic lupus erythematosus analysed by proliferative response to nucleoplasmic proteins on nitrocellulose immunoblots.

Authors:  B N Pham; L Prin; D Gosset; P Y Hatron; B Devulder; A Capron; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

6.  A novel function of B lymphocytes from normal mice to suppress autoimmunity in (NZB x NZW)F1 mice.

Authors:  S Ono; D Shao; S Yamada; Y Yang; M Yamashita; T Hamaoka
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 7.  B and T cell antigen receptor repertoires in lupus/arthritis murine models.

Authors:  A N Theofilopoulos; P A Singer; R Kofler; D H Kono; M A Duchosal; R S Balderas
Journal:  Springer Semin Immunopathol       Date:  1989

Review 8.  Contributions of B cells to lupus pathogenesis.

Authors:  Allison Sang; Ying-Yi Zheng; Laurence Morel
Journal:  Mol Immunol       Date:  2013-12-12       Impact factor: 4.407

Review 9.  T cell repertoire and autoimmune diseases.

Authors:  L Imberti; A Sottini; D Primi
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

10.  In vivo induction of IgG anti-DNA antibody by autoreactive mixed haplotype A beta z/A alpha d MHC class II molecule-specific CD4+ T-cell clones.

Authors:  M Tokushima; S Koarada; S Hirose; Y Gotoh; H Nishimura; T Shirai; K Miyake; M Kimoto
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.